We can now understand AGN's motive for the take-over of MAPP at such a bargain price!
There is no argument over the high efficacy of MAPP's Levadex innovative delivery system; however, the complexity of bringing this process to a successful FDA approval is proving to be most challenging for a small cap concern.
AGN has the built-in structure, reservoir of intellectual capital, and excellent leadership to successfully bring this complex process to a successful FDA approval.
Plus, with the AGN's reiteration of their 2013 revenue and earnings guidelines, I am content -- like I've always been -- to place Inhaled Levadex, in the awesome AGN pipeline that will deliver sustained growth over the next 5 to 8 years, and perhaps beyond.
I am sure AGN's management understands that it is best to get the process done quickly but efficiently, instead of hurried and sloppy.
This is an excellent opportunity for longs to add to their positions!